SyntekaBio

SyntekaBio Equity Turnover

The Equity Turnover of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 0.11.

Equity Turnover

0.11

YoY

2,126.53%

Last updated:

Equity Turnover of SyntekaBio is 2025 0.11 . Equity Turnover of SyntekaBio was 2024 0.00 . It decreases by 2,126.53% higher compared to the previous year.

The SyntekaBio Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.17 KRW
Jan 1, 2019
0.01 KRW
Jan 1, 2020
0.01 KRW
Jan 1, 2021
0.01 KRW
Jan 1, 2022
0.01 KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
0.00 KRW
Jan 1, 2025
0.11 KRW
The SyntekaBio Equity Turnover history
YEAREquity TurnoverYoY
0.11+2,126.53%
0.00+22.64%
0.00-49.05%
0.01-32.34%
0.01-21.91%
0.01+46.68%
0.01-94.27%
0.17-1,220.29%
-0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Equity Turnover of SyntekaBio is 0.11 in 2025.

On Eulerpool you can find the complete historical development of Equity Turnover SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SyntekaBio

All Key Metrics — SyntekaBio